Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane
NCT ID: NCT00291798
Last Updated: 2006-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
98 participants
INTERVENTIONAL
2000-09-30
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rate of remission
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Postmenopausal patients (\> 1 year following outset of menopause and/or postmenopausal hormonal profile)
* Clinical staging: T2 (\> 3 cm), T3, T4a-c, N0-1
* Hormone receptor positivity, i.e. estrogen and/or progesterone receptor \> 10 fmol/mg cytosolic protein or ER-ICA-positive and/or PgR-ICA-positive. Positivity of + (low-grade) in one hormone receptor is only eligible in the presence of positivity in the other hormone receptor.
* no internal contraindication
* life expectation \> 6 month
* written informed consent
Exclusion Criteria
* manifest second malignant tumor (except basalioma or in situ carcinoma of cervix uteri)
* uncontrolled internal disease i.e. diabetes mellitus, cardiac disease (NYHA III/IV)
* thromboembolic disease
* inflammatory mamma carcinoma
* existence of distant metastases
* former or simultaneously therapy with antioestrogens, aromatase inhibitors, cytostatics or radiotherapy
* corticosteroids before and during the study (except inhalant application)
* lack of compliance
59 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmacia Austria GmbH
UNKNOWN
Austrian Breast & Colorectal Cancer Study Group
NETWORK
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brigitte Mlineritsch, MD
Role: STUDY_CHAIR
Austrian Breast & Colorectal Cancer Study Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital of Guessing
Güssing, Burgenland, Austria
State Hospital Klagenfurt, Surgery
Klagenfurt, Carinthia, Austria
State Hospital Wolfsberg
Wolfsberg, Carinthia, Austria
Hospital of Wiener Neustadt
Wiener Neustadt, Lower Austria, Austria
Paracelsus Medical University Salzburg, Oncology
Salzburg, Salzburg, Austria
Gynaegological Medical University of Graz
Graz, Styria, Austria
Medical University of Graz, Oncology
Graz, Styria, Austria
Hospital BHS Linz
Linz, Upper Austria, Austria
General Hospital Linz
Linz, Upper Austria, Austria
Medical University of Vienna, General Hospital
Vienna, Vienna, Austria
Hanusch Hospital
Vienna, Vienna, Austria
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABCSG-17
Identifier Type: -
Identifier Source: org_study_id